Exposure to Bupropion-SR vs. Placebo is associated with reductions in smoking among persons receiving methadone with no stated interest in smoking cessation
Addictive Behaviors · 2025
DOI: 10.1016/j.addbeh.2024.108202 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Addictive Behaviors, 2025. Verfasst von Orrin D Ware und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina at Chapel Hill School of Social Work, Chapel Hill, NC, United States. Electronic address: oware@unc.edu. Hauptthemen laut MEDLINE: Bupropion, Methadone, Smoking Cessation, Opiate Substitution Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: NIDA NIH HHS.
Abstract (Originalsprache)
Smoking is prevalent among individuals receiving methadone treatment. Reducing smoking among this population is needed as smoking is a leading cause of morbidity and preventable death. Smoking cessation interventions for persons receiving medication for opioid use disorder have yielded small changes in abstinence. Bupropion-SR was developed as an anti-depressant medication and is a first-line medication for smoking cessation. There is limited research on the effectiveness of bupropion-SR on smoking cessation among individuals receiving medication for opioid use disorder. This study is a secondary analysis of N = 72 adults enrolled in methadone treatment who endorsed smoking cigarettes. Participants were randomized to receive bupropion-SR 150 mg twice-daily (n = 35) or placebo (n = 37) in the primary study that examined bupropion-SR on cocaine use outcomes over a 30-weeks. Mixed model analyses examined secondary changes in self-reported cigarettes smoked, a self-reported measure of nicotine dependence, and quantitative urinary cotinine values. The longitudinal analysis of self-reported daily cigarettes identified no main effects of group and week however a significant interaction between group and week revealed that persons receiving bupropion-SR group reported less smoking early in the intervention. Longitudinal evaluation of changes in urinary cotinine revealed a significant main effect of week but no main effect of group or group x week interaction. Data suggest that bupropion-SR significantly decreased the number of self-reported cigarettes smoked relative to placebo and reduced nicotine dependence severity by the end of the study. Follow-up studies are needed as these decreases were not identified throughout the full study period or at termination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of North Carolina at Chapel Hill School of Social Work, Chapel Hill, NC, United States. Electronic address: oware@unc.edu.
- Friends Research Institute, Baltimore, MD, United States. Electronic address: mstitzer@jhmi.edu.
- Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: annieumbricht@me.com.
- Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: kdunn9@jhmi.edu.
Förderung
- NIDA NIH HHS
Zitieren
APA
Ware, O. D., Stitzer, M. L., Umbricht, A., & Dunn, K. E. (2025). Exposure to Bupropion-SR vs. Placebo is associated with reductions in smoking among persons receiving methadone with no stated interest in smoking cessation. Addictive Behaviors. https://doi.org/10.1016/j.addbeh.2024.108202
Vancouver
Ware OD, Stitzer ML, Umbricht A, Dunn KE. Exposure to Bupropion-SR vs. Placebo is associated with reductions in smoking among persons receiving methadone with no stated interest in smoking cessation. Addictive Behaviors. 2025. doi:10.1016/j.addbeh.2024.108202
BibTeX
@article{Ware2025,
author = {Ware, Orrin D and Stitzer, Maxine L and Umbricht, Annie and Dunn, Kelly E},
title = {Exposure to Bupropion-SR vs. Placebo is associated with reductions in smoking among persons receiving methadone with no stated interest in smoking cessation},
journal = {Addictive Behaviors},
year = {2025},
doi = {10.1016/j.addbeh.2024.108202}
}
EUVIMED